An interventional study of Therapeutic Plasma Exchange (TPE) in Septic Shock, sponsored by Hannover Medical School. Recruiting at 25 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-13.
Sponsored by Hannover Medical School · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Shock, Septic with a site in Germany — 7 open to participants now, 7 under way, none of them phase 3. Shock, Septic · Germany.
Among the 56 studies in Shock, Septic with a site in Germany, this one is the 16th largest by planned enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 with no phase, and was the 53rd registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →7 of the 56 studies in Shock, Septic with a site in Germany are open now. Recruiting first, the newest first:
Artcline GmbH · Sites in Germany
Ages 18+
Charite University, Berlin, Germany · Sites in Germany
Ages 18+
CytoSorbents, Inc · Sites in Germany, Austria, Italy and 3 more countries
Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps · Sites in Germany
Ages 18–99
RWTH Aachen University · Sites in Germany, Austria
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 8
First in 2002; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 274 is above the median of 78 across 639 interventional studies indexed under Shock, Septic.
Median enrollment 277 across the 29 interventional studies, 275 across the 26 observational. Of the 33 that completed or were terminated, 4 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 56 have an industry lead sponsor. The 10 most frequent:
Hannover Medical School is the lead sponsor of 202 studies on the registry; 25 are open to participants now.
Hannover Medical School has 3 studies filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
4 of the studies in Shock, Septic with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05688774Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe SepsStudy of Progression of Community Acquired Pneumonia in the Hospital in Patients With More Severe Preexisting Diseases and Immunosuppression | 2027-02-28 |
| NCT07388628Artcline GmbHARTICE® Real Data Collection & Observational Trial, Phase 4 Study | 2027-09 |
| NCT03334006RWTH Aachen UniversityProspective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis | 2027-09 |
| NCT07817043University Medicine GreifswaldMicrobiology Operations & Time Optimization in Sepsis | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 56 studies in Shock, Septic with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Randomized, prospective, multicenter, open-label, controlled, parallel-group interventional trial to test the adjunctive effect of therapeutic plasma exchange in patients with early septic shock.
Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to an infection; in septic shock profound circulatory, cellular and metabolic abnormalities are associated with an even higher mortality. Sepsis is a major healthcare problem, affecting millions of individuals around the world each year. Its incidence appears to be rising, and the mortality caused by septic shock in Germany in 2015 remains extraordinarily high (58.8%). It is well known - from the pathophysiological point of view - that these patients do not die from their infection per se but rather from multiple organ failure caused by their own overwhelming host response. This fact is so fundamental that it has been implemented as a key part of the 2016 sepsis definition (SEPSIS-3). Despite tremendous efforts during the last decades, innovative approaches targeting this fundamental hallmark of the disease, thereby reducing organ dysfunction, are lacking. Undoubtedly, there is an unmet need to expand the current standard of care for these patients by a more specific intervention.
The investigators hypothesize that early Therapeutic Plasma Exchange (TPE) in the most severely ill individuals will dampen the injurious maladaptive host response by removing injurious mediators thereby limiting organ dysfunction. The potential impact of this trial is of immense clinical relevance as it evaluates a promising adjunctive treatment option for a patient cohort suffering from an extraordinary high mortality. A positive trial result could truly change the current standard of care (SOC) - that is mostly supportive - of septic shock patients. Of note, there is neither a patent nor a direct commercial interest in such a trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1 x TPE with donor Fresh Frozen Plasma (FFPs) (1.2 x individual plasma volume) within the first 6 hrs after randomization. A second TPE can be performed if the patient remains vasopressor dependent ≥ 0.4 ug/kg/min within 24 hours after the first intervention.
Device: Therapeutic Plasma Exchange (TPE)
Non-interventional standard of care
The TPE treatment will be initiated within 6 hrs after randomization. Duration of TPE treatment is approximately 120-180 minutes. An additional second TPE can be performed if the patient remains vasopressor dependent ≥ 0.4 ug/kg/min after 24 hours following the first TPE procedure. Both unfractionated heparin (UFH) and citrate may be used as anticoagulant medication. To ensure treatment comparability between different patients, we will replace plasma in a fixed ratio of 1.2 x the individual patient's total plasma fluid.
28-day mortality
Time frame: from randomization up to 28 days following randomization
Mean daily Sequential Organ Failure Score (SOFA) score over the first 7 days (KEY secondary outcome)
Per-patient mean daily SOFA score over the first 7 days, ranging from 0-24 points with higher scores indicating more severe organ dysfunction
Time frame: from randomization up to 7 days following randomization
Organ support free days until day 28 (KEY secondary outcome)
total days free of invasive ventilation, vasopressors/inotrops and renal replacement therapy (RRT) until day 28
Time frame: from randomization up to 28 days following randomization
90-day mortality
Time frame: from randomization up to 90 days following randomization
Intensive Care unit (ICU) length of stay
total days in ICU
Time frame: from randomization until ICU discharge
Hospital length of stay
total days in hospital
Time frame: from randomization until hospital discharge
Basic Hemodynamics
includes: Norepinephrine- \[µg/kg/min\], Dobutamine \[µg/kg/min\], Epinephrine- \[µg/kg/min\] and Vasopressin-dose \[U/kg/min\], Vasocative-inotropic (VIS) Score with higher scores indicating higher vasopressor/inotropic support, Mean arterial pressure (MAP, \[mmHg\]), Heart Rate (HR, \[1/min\]), Central venous pressure (CVP, \[mmHg\]) and Central-Venous Oxygen Saturation (ScvO2, \[%\]) at 0 and 12 hrs, d1-7
Time frame: at days 1-7 following randomization
Extended Hemodynamics
includes: Cardiac Index (CI, \[l/min/m2\]), Global End-Diastolic Volume Index (GEDI, \[ml/m2\]), Sytemic Vascular Resistance Index (SVRI, \[dyn\*s\*cm-5\*m2\]), Stroke Volume Variation (SVV, \[%\] ), Extravascular Lung Water Index (ELWI, \[ml/kg\]) and Pulmonar Vascular Permeability Index (PVPI) at at 0 and 12 hrs, d1-7
Time frame: at days 1-7 following randomization
Arterial blood gas analysis
includes: pH, PCO2 \[mmHg\], HCO3- \[mmol\], PO2 \[mmHg\], Lactate \[mmol/l\] at 0 and 12 hrs, d1-7
Time frame: at days 1-7 following randomization
Respiratory function
includes: pO2/FiO2, Tidal Volume (VT, \[ml\]), Positive End-Exspiratory Pressure (PEEP, \[cmH2O\]), Peak-Pressure (Ppeak, \[cmH2O\]), Plateau-Pressure (Pplat, \[cmH2O\]), Respiratory Rate (RR, \[1/min\]), Inspiratory Time (Tinsp, \[s\]), Inspiratory-Flow and End-tidal-CO2 (etCO2, \[mmHg\]) at 0 and 12 hrs, d1-7
Time frame: at days 1-7 following randomization
Renal function
includes: Presence of Acute kindey injury (AKI), AKI stage (KDIGO definition) stage 1-3 with higher stage indicating worse renal function, Need for Renal Replacement Therapy (RRT), Estimated Glomerular Filtration Rate (eGFR following CKD-EPI equation) \[ml/min\], Fluid intake \[ml/d\], Urine output \[ml/d\], Ultrafiltration and Net daily fluid balance \[ml/d\] at 0 and 12 hrs, d1-7 and at ICU discharge
Time frame: at days 1-7 following randomization and at ICU discharge
Liver Function
includes: Bilirubin, Aspartate aminotransferase (AST, \[U/l\]), Alanine aminotransferase (ALT, \[U/l\]), Alkaline phosphatase (AP, \[U/l\]), Gamma-glutamyl transferase (GGT, \[U/l\]), Cholinesterase (CHE, \[kU/l\]) and Albumin \[g/l\] at 0 and 12 hrs, d1-7 and at ICU discharge
Time frame: at days 1-7 following randomization and at ICU discharge
Sepsis associated coagulopathy
includes: Differential blood count including schistocytes \[%\], Fibrinogen \[g/l\] , D-Dimer \[mg/l\], International Normalized Ratio (INR), Lactate dehydrogenase (LDH, \[U/l\]), Antithrombin-III (AT-III, \[%\]), Protein C \[%\] and International Society on Thrombosis and Hemostasis- Disseminated Intravscular Coagulation Score (ISTH-DIC, \[U/l\]) ranging from 0-8 points with higher values indication more severe DIC at 0 and 12 hrs, d1-7, A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13, \[%\]) and von-Willebrand-Factor Antigen (vWF:Ag,\[IU/l\]) at 0 and 24 hrs
Time frame: at days 1-7 following randomization
Inflammatory response
includes: C-reactive protein (CRP, \[mg/l\]), Procalcitonin (PCT, \[ug/l\]), Interleukin-6 (IL-6, \[ng/ml\]), Ferritin \[ug/l\] and Neutrophil/Lymphocyte ratio at 0 and 12 hrs, d1-7
Time frame: at days 1-7 following randomization
Cardiac function
includes: Creatine kinase (CK, \[U/l\]), Myoglobin \[ug/l\], Troponin T \[ng/l\], NT-proBNP \[ng/l\] at 0 and 12 hrs, d1-7 and at ICU discharge
Time frame: at days 1-7 following randomization and at ICU discharge
Secondary infections
includes: incidence and type of secondary infections until ICU and hospital discharge, incidence of viral (HSV, EBV, CMV) reactivation at d7 and d14
Time frame: from randomization until hospital discharge
Safety Endpoints
includes: Incidence of bleeding, allergic reactions, Transfusion associated lung injury (TRALI), severe thrombocytopenia (\< 5000/µl) and (other) severe adverse events (SAEs)
Time frame: from randomization until day 7 following randomization
Not enrolling at this site — choose another above.
Plan to share: No
Started Feb 2025 (actual). Primary completion is estimated for Feb 2028, 36 months after the start.
Of 165 non-industry interventional studies with no phase under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 36 months is above that.
Counting every sponsor, half of 173 studies reached it within 25 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.